
Title:
Scleroderma
Text:
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}This article is about the disease. For the mushroom, see Scleroderma (fungus).
Not to be confused with scleredema.
Group of autoimmune diseases resulting in abnormal growth of connective tissue
Medical condition.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}SclerodermaA type of localized scleroderma known as morpheaSpecialtyRheumatologyUsual onsetMiddle age[1]TypesLocalized, systemic scleroderma[2]CausesUnknown[2]Risk factorsFamily history, certain genetic factors, exposure to silica[3][4][5]Diagnostic methodBased on symptoms, skin biopsy, blood tests[6]Differential diagnosisMixed connective tissue disease, systemic lupus erythematosus, polymyositis, dermatomyositis[1]TreatmentSupportive care[1]MedicationCorticosteroids, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs)[2]PrognosisLocalized: Normal life expectancy[7]Systemic: Decreased life expectancy[3]Frequency3 per 100,000 per year (systemic)[3]
Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs.[2][6][8] The disease can be either localized to the skin or involve other organs, as well.[2] Symptoms may include areas of thickened skin, stiffness, feeling tired, and poor blood flow to the fingers or toes with cold exposure.[1] One form of the condition, known as CREST syndrome, classically results in calcium deposits, Raynaud's syndrome, esophageal problems, thickening of the skin of the fingers and toes, and areas of small, dilated blood vessels.[1]
The cause is unknown, but it may be due to an abnormal immune response.[2] Risk factors include family history, certain genetic factors, and exposure to silica.[3][4][5] The underlying mechanism involves the abnormal growth of connective tissue, which is believed to be the result of the immune system attacking healthy tissues.[6] Diagnosis is based on symptoms, supported by a skin biopsy or blood tests.[6]
While no cure is known, treatment may improve symptoms.[2] Medications used include corticosteroids, methotrexate, and non-steroidal anti-inflammatory drugs (NSAIDs).[2] Outcome depends on the extent of disease.[3] Those with localized disease generally have a normal life expectancy.[7] In those with systemic disease, life expectancy can be affected, and this varies based on subtype.[3] Death is often due to lung, gastrointestinal, or heart complications.[3]
About three per 100,000 people per year develop the systemic form.[3] The condition most often begins in middle age.[1] Women are more often affected than men.[1] Scleroderma symptoms were first described in 1753 by Carlo Curzio[9] and then well documented in 1842.[10] The term is from the Greek skleros meaning "hard" and derma meaning "skin".[11][12]

Contents

1 Signs and symptoms
2 Cause
3 Pathophysiology
4 Diagnosis

4.1 Differential
4.2 Classification


5 Treatment
6 Prognosis
7 Epidemiology
8 Pregnancy
9 See also
10 References
11 External links



Signs and symptoms[edit]
  Arm of a person with scleroderma showing skin lesions
  Dark, shiny skin on distal phalanges of both hands in systemic sclerosis
Potential signs and symptoms include:[13][14][15]

Cardiovascular: Raynaud's phenomenon (is the presenting symptom in 30% of affected persons, occurs in 95% of affected individuals at some time during their illness); healed pitting ulcers on the fingertips; skin and mucosal telangiectasis; palpitations, irregular heart rate and fainting due to conduction abnormalities, hypertension, and congestive heart failure
Digestive: gastroesophageal reflux disease, bloating, indigestion, loss of appetite, diarrhoea alternating with constipation, sicca syndrome and its complications, loosening of teeth, and hoarseness (due to acid reflux).
Pulmonary: progressive worsening of shortness of breath, chest pain (due to pulmonary artery hypertension) and dry, persistent cough due to interstitial lung disease
Musculoskeletal: joint, muscle aches, loss of joint range of motion, carpal tunnel syndrome, and muscle weakness
Genitourinary: erectile dysfunction, dyspareunia, kidney problems, or kidney failure
Other: facial pain due to trigeminal neuralgia, hand paresthesias, headache, stroke, fatigue, calcinosis, and weight loss
Cause[edit]
Scleroderma is caused by genetic and environmental factors.[4][5][16][17] Mutations in HLA genes seem to play a crucial role in the pathogenesis of some cases; likewise silica, aromatic and chlorinated solvents, ketones, trichloroethylene, welding fumes, and white spirits exposure seems to contribute to the condition in a small proportion of affected persons.[4][5][16][17][18]

Pathophysiology[edit]
It is characterised by increased synthesis of collagen (leading to the sclerosis), damage to small blood vessels, activation of T lymphocytes, and production of altered connective tissue.[19] Its proposed pathogenesis is the following:[20][21][22][23][24]

It begins with an inciting event at the level of the vasculature, probably the endothelium. The inciting event is yet to be elucidated, but may be a viral agent, oxidative stress, or autoimmune. Endothelial cell damage and apoptosis ensue, leading to the vascular leakiness that manifests in early clinical stages as tissue oedema. At this stage, it is predominantly a Th1- and Th17-mediated disease.
After this, the vasculature is further compromised by impaired angiogenesis and impaired vasculogenesis (fewer endothelial progenitor cells), likely related to the presence of antiendothelinal cell antibodies (AECA). Despite this impaired angiogenesis, elevated levels of pro-angiogenic growth factors such as PDGF and VEGF is often seen in persons with the condition. The balance of vasodilation and vasoconstriction becomes askew, and the net result is vasoconstriction. The damaged endothelium then serves as a point of origin for blood-clot formation and further contributes to ischaemia-reperfusion injury and the generation of reactive oxygen species. These later stages are characterised by Th2 polarity.
The damaged endothelium upregulates adhesion molecules and chemokines to attract leucocytes, which enables the development of innate and adaptive immune responses, including loss of tolerance to various oxidised antigens, which includes topoisomerase I. B cells mature into plasma cells, which furthers the autoimmune component of the condition. T cells differentiate into subsets, including Th2 cells, which play a vital role in tissue fibrosis. Anti–topoisomerase 1 antibodies, in turn, stimulate type I interferon production.
Fibroblasts are recruited and activated by multiple cytokines and growth factors to generate myofibroblasts. Dysregulated transforming growth factor β (TGF-β) signalling in fibroblasts and myofibroblasts has been observed in multiple studies of scleroderma-affected individuals. Activation of fibroblasts and myofibroblasts leads to excessive deposition of collagen and other related proteins, leading to fibrosis. B cells are implicated in this stage, IL-6 and TGF-β produced by the B cells decrease collagen degradation and increase extracellular matrix production. Endothelin signalling is implicated in the pathophysiology of fibrosis.[25]
Vitamin D is implicated in the pathophysiology of the disease. An inverse correlation between plasma levels of vitamin D and scleroderma severity has been noted, and vitamin D is known to play a crucial role in regulating (usually suppressing) the actions of the immune system.[26]

Diagnosis[edit]
Typical scleroderma is classically defined as symmetrical skin thickening, with about 70% of cases also presenting with Raynaud's phenomenon, nail-fold capillary changes, and antinuclear antibodies. Affected individuals may experience systemic organ involvement. No single test for scleroderma works all of the time, hence diagnosis is often a matter of exclusion. Atypical scleroderma may show any variation of these changes without skin changes or with finger swelling only.[27]
Laboratory testing can show antitopoisomerase antibodies, like anti-scl70 (causing a diffuse systemic form), or anticentromere antibodies (causing a limited systemic form and the CREST syndrome). Other autoantibodies can be seen, such as anti-U3 or anti-RNA polymerase.[28]
Antidouble-stranded DNA  autoantibodies are likely to be present in serum.[citation needed]

Differential[edit]
Diseases that are often in the differential include:[29]

Eosinophilia is a condition in which too many eosinophils  (a type of immune cell that attacks parasites and is involved in certain allergic reactions) are present in the blood.
Eosinophilia-myalgia syndrome is a form of eosinophilia caused by L-tryptophan supplements.
Eosinophilic fasciitis affects the connective tissue surrounding skeletal muscles, bones, blood vessels, and nerves in the arms and legs.
Graft-versus-host disease is an autoimmune condition that occurs as a result of bone-marrow transplants in which the immune cells from the transplanted bone marrow attack the host's body.
Mycosis fungoides is a type of cutaneous T cell lymphoma, a rare cancer that causes rashes all over the body.
Nephrogenic systemic fibrosis is a condition usually caused by kidney failure that results in fibrosis (thickening) of the tissues.
Primary biliary cirrhosis is an autoimmune disease of the liver.
Primary pulmonary hypertension
Complex regional pain syndrome
Classification[edit]
Scleroderma is characterised by the appearance of circumscribed or diffuse, hard, smooth, ivory-colored areas that are immobile and which give the appearance of hidebound skin, a disease occurring in both localised and systemic forms:[30]

.mw-parser-output .div-col{margin-top:0.3em;column-width:30em}.mw-parser-output .div-col-small{font-size:90%}.mw-parser-output .div-col-rules{column-rule:1px solid #aaa}.mw-parser-output .div-col dl,.mw-parser-output .div-col ol,.mw-parser-output .div-col ul{margin-top:0}.mw-parser-output .div-col li,.mw-parser-output .div-col dd{page-break-inside:avoid;break-inside:avoid-column}
Localised scleroderma
Localised morphea
Morphea-lichen sclerosus et atrophicus overlap
Generalised morphea
Atrophoderma of Pasini and Pierini
Pansclerotic morphea
Morphea profunda
Linear scleroderma
Systemic scleroderma
CREST syndrome
Progressive systemic sclerosis

Treatment[edit]
No cure for scleroderma is known, although relief of symptoms is often achieved; these include the:[13][31]

Raynaud's phenomenon with vasodilators such as calcium channel blockers, alpha blockers, serotonin receptor antagonists, angiotensin II receptor inhibitors, statins, local nitrates or iloprost
Digital ulcers with phosphodiesterase 5 inhibitors (e.g., sildenafil) or iloprost
Prevention of new digital ulcers with bosentan
Malnutrition, secondary to intestinal flora overgrowth with tetracycline antibiotics such as tetracycline
Interstitial lung disease with cyclophosphamide, azathioprine with or without corticosteroids
Pulmonary arterial hypertension with endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and prostanoids
Gastrooesophageal reflux disease with antacids or prokinetics
Kidney crises with angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists
Systemic disease-modifying treatment with immunosuppressants is often used.[16][32][33][34][35][36] Immunosuppressants used in its treatment include azathioprine, methotrexate, cyclophosphamide, mycophenolate, intravenous immunoglobulin, rituximab, sirolimus, alefacept, and the tyrosine kinase inhibitors, imatinib, nilotinib, and dasatinib.[16][31][32][33][34][35][36][37]
Experimental therapies under investigation include endothelin receptor antagonists, tyrosine kinase inhibitors, beta-glycan peptides, halofuginone, basiliximab, alemtuzumab, abatacept, and haematopoietic stem cell transplantation.[38][39]



Immunomodulatory agents in the treatment of scleroderma


INN
Mechanism of action[40][41]
Route of administration[40]
Pregnancy category[40][42]
Major toxicities[40]


Alefacept
Monoclonal antibody to inhibit T lymphocyte activation by binding to CD2 portion of human leukocyte function antigen-3.
IM
B (US)
Malignancies, injection site reactions, blood clots, lymphopenia, hepatotoxicity and infections.


Azathioprine
Purine analogue that inhibits lymphocyte proliferation via conversion to mercaptopurine
PO, IV
D (Au)
Myelosuppression and rarely malignancy, hepatitis, infection, hepatic sinusoidal obstruction syndrome and hypersensitivity reactions.


Cyclophosphamide
Nitrogen mustard that cross-links DNA base pairs, leading to breakages and triggering apoptosis in haematopoietic cells.
PO, IV
D (Au)
Vomiting, myelosuppression, haemorrhagic cystitis and rarely heart failure, pulmonary fibrosis, hepatic sinusoidal obstruction syndrome, malignancy and SIADH


Dasatinib
Tyrosine kinase inhibitor against various proangiogenic growth factors (including PDGF and VEGF).
PO
D (Au)
Fluid retention, myelosuppression, haemorrhage, infections, pulmonary hypertension, electrolyte anomalies and uncommonly hepatotoxicity, heart dysfunction/failure, myocardial infarction, QT interval prolongation, renal failure and hypersensitivity.


Imatinib
As above
PO
D (Au)
As above and rarely: GI perforation, avascular necrosis and rhabdomyolysis


Immunoglobulin
Immunoglobulin, modulates the immune system.
IV
N/A
Varies


Methotrexate
Antifolate; inhibits dihydrofolate reductase.
PO, IV, IM, SC, IT
D (Au)
Myeosuppression, pulmonary toxicity, hepatotoxicity, neurotoxicity and rarely kidney failure, hypersensitivity reactions, skin and bone necrosis, and osteoporosis


Mycophenolate
Inosine monophosphate dehydrogenase inhibitor, leading to reduced purine biosynthesis in lymphocytes.
PO, IV
D (Au)
Myelosuppression, blood clots, less commonly GI perforation/haemorrhage and rarely pancreatitis, hepatitis, aplastic anaemia and pure red cell aplasia.


Nilotinib
As per dasatinib
PO
D (Au)
As per imatinib


Rituximab
Monoclonal antibody against CD20, which is expressed on B lymphocytes
IV
C (Au)
Infusion-related reactions, infection, neutropenia, reduced immunoglobulin levels, arrhythmias, less commonly anaemia, thrombocytopenia, angina, myocardial infarction, heart failure, and rarely haemolytic anaemia, aplastic anaemia, serum sickness, severe skin conditions, pulmonary infiltrates, pneumonitis, cranial neuropathy (vision or hearing loss) and progressive multifocal leucoencephalopathy.


Sirolimus
mTOR inhibitor, thereby reducing cytokine-induced lymphocyte proliferation.
PO
C (Au)
Neutropenia, hypokalaemia, interstitial lung disease, pericardial effusion, pleural effusion, less commonly pulmonary haemorrhage, nephrotic syndrome, and rarely hepatotoxicity and lymphoedema.


PO = Oral. IV = Intravenous. IM = Intramuscular. SC = Subcutaneous. IT = Intrathecal.
The preferred pregnancy category, above, is Australian, if available. If unavailable, an American one is substituted.


Prognosis[edit]
As of 2012[update], the five-year survival rate for systemic scleroderma was about 85%, whereas the 10-year survival rate was just under 70%.[43] This varies according to the subtype; while localized scleroderma rarely results in death, the systemic form can, and the diffuse systemic form carries a worse prognosis than the limited form. The major scleroderma-related causes of death are: pulmonary hypertension, pulmonary fibrosis, and scleroderma renal crisis.[28] People with scleroderma are also at a heightened risk for contracting cancers (especially liver, lung, haematologic, and bladder cancers), and perhaps, cardiovascular disease.[44][45][46][47][48][49][excessive citations]
According to a study of an Australian cohort, between 1985 and 2015, the average life expectancy of a person with scleroderma increased from 66 years to 74 years (around 8 years less than the average Australian life expectancy of 82 years).[50]

Epidemiology[edit]
Scleroderma most commonly first presents between the ages of 20 and 50 years, although any age group can be affected.[13][28] Women are four to nine times more likely to develop scleroderma than men.[28]
This disease is found worldwide.[28] In the United States, prevalence is estimated at 240 per million and the annual incidence of scleroderma is 19 per million people.[28] Likewise in the United States, it is slightly more common in African Americans than in their White counterparts. Choctaw Native Americans are more likely than Americans of European descent to develop the type of scleroderma that affects internal organs.[28] In Germany, the prevalence is between 10 and 150 per million people, and the annual incidence is between three and 28 per million people.[43] In South Australia, the annual incidence is 23 per million people, and the prevalence 233 per million people.[51] Scleroderma is less common in the Asian population.[52]

Pregnancy[edit]
Scleroderma in pregnancy is a complex situation; it increases the risk to both mother and child.[53] Overall, scleroderma is associated with reduced fetal weight for gestational age.[53] The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, mycophenolate, etc., so careful avoidance of such drugs during pregnancy is advised.[53] In these cases hydroxychloroquine and low-dose corticosteroids might be used for disease control.[53]

See also[edit]
Congenital fascial dystrophy
Chi Chi DeVayne, (suffered from scleroderma in the years leading up to her death)
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b c d e f g .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Scleroderma". NORD (National Organization for Rare Disorders). 2007. Archived from the original on 8 September 2016. Retrieved 14 July 2017.

^ Jump up to: a b c d e f g h "Scleroderma". GARD. 2017. Archived from the original on 25 January 2017. Retrieved 14 July 2017.

^ Jump up to: a b c d e f g h Jameson, Larry (2018). "Chapter 353". Harrison's Principles of Internal Medicine (20th ed.). McGraw Hill.

^ Jump up to: a b c d Barnes J, Mayes MD (March 2012). "Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers". Current Opinion in Rheumatology. 24 (2): 165–70. doi:10.1097/BOR.0b013e32834ff2e8. PMID 22269658. S2CID 24050211.

^ Jump up to: a b c d Greenblatt MB, Aliprantis AO (January 2013). "The immune pathogenesis of scleroderma: context is everything". Current Rheumatology Reports. 15 (1): 297. doi:10.1007/s11926-012-0297-8. PMC 3539168. PMID 23288576.

^ Jump up to: a b c d "Handout on Health: Scleroderma". NIAMS. August 2016. Archived from the original on 4 July 2017. Retrieved 15 July 2017.

^ Jump up to: a b Unsal, Erbil (2006). Current Opinions in Pediatric Rheumatology. Nova Publishers. p. 302. ISBN 9781594548710. Archived from the original on 2017-09-06.

^ Denton, Christopher P; Khanna, Dinesh (October 2017). "Systemic sclerosis". The Lancet. 390 (10103): 1685–99. doi:10.1016/s0140-6736(17)30933-9. PMID 28413064. S2CID 22247432.

^ Mackay, Ian R.; Rose, Noel R. (2006). The Autoimmune Diseases. Academic Press. p. 369. ISBN 9780080454740.

^ Firestein, Gary S.; Kelley, William N.; Budd, Ralph C. (2012). Kelley's Textbook of Rheumatology. Elsevier Health Sciences. p. 1366. ISBN 978-1437717389. Archived from the original on 2017-08-04.

^ Harper, Douglas. "scleroderma". Online Etymology Dictionary.

^ σκληρός, δέρμα. Liddell, Henry George; Scott, Robert; A Greek–English Lexicon at the Perseus Project.

^ Jump up to: a b c Hajj-ali, RA (June 2013). "Systemic Sclerosis". Merck Manual Professional. Merck Sharp & Dohme Corp. Archived from the original on 6 March 2014. Retrieved 5 March 2014.

^ Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012).  Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS (eds.). "Scleroderma Clinical Presentation". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 5 March 2014.

^ Longo, D; Fauci, A; Kasper, D; Hauser, S; Jameson, J; Loscalzo, J (2011). Harrison's Principles of Internal Medicine (18th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07174889-6.{{cite book}}:  CS1 maint: multiple names: authors list (link)[page needed]

^ Jump up to: a b c d Balbir-Gurman A, Braun-Moscovici Y (February 2012). "Scleroderma – new aspects in pathogenesis and treatment". Best Practice & Research. Clinical Rheumatology. 26 (1): 13–24. doi:10.1016/j.berh.2012.01.011. PMID 22424190.

^ Jump up to: a b Dospinescu P, Jones GT, Basu N (March 2013). "Environmental risk factors in systemic sclerosis". Current Opinion in Rheumatology. 25 (2): 179–83. doi:10.1097/BOR.0b013e32835cfc2d. PMID 23287382. S2CID 37543720.

^ Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, Bravard P, Noël D, Cailleux AF, Weber J, Lagoutte P, Benichou J, Levesque H (February 2014). "Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature". Autoimmunity Reviews. 13 (2): 151–56. doi:10.1016/j.autrev.2013.10.002. PMID 24129037.

^ Valančienė G, Jasaitienė D, Valiukevičienė S (2010). "Pathogenesis and treatment modalities of localized scleroderma" (PDF). Medicina. 46 (10): 649–56. doi:10.3390/medicina46100092. PMID 21393982. Archived (PDF) from the original on 2014-03-06.

^ Katsumoto TR, Whitfield ML, Connolly MK (2011). "The pathogenesis of systemic sclerosis". Annual Review of Pathology. 6: 509–37. doi:10.1146/annurev-pathol-011110-130312. PMID 21090968.

^ Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (August 2011). "Angiogenic cytokines and growth factors in systemic sclerosis". Autoimmunity Reviews. 10 (10): 590–94. doi:10.1016/j.autrev.2011.04.019. PMID 21549861.

^ Cipriani P, Marrelli A, Liakouli V, Di Benedetto P, Giacomelli R (August 2011). "Cellular players in angiogenesis during the course of systemic sclerosis". Autoimmunity Reviews. 10 (10): 641–46. doi:10.1016/j.autrev.2011.04.016. PMID 21549220.

^ Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G (August 2011). "B cells in systemic sclerosis: a possible target for therapy". Autoimmunity Reviews. 10 (10): 624–30. doi:10.1016/j.autrev.2011.04.013. PMID 21545850.

^ Hunzelmann N, Krieg T (May 2010). "Scleroderma: from pathophysiology to novel therapeutic approaches". Experimental Dermatology. 19 (5): 393–400. doi:10.1111/j.1600-0625.2010.01082.x. PMID 20507361. S2CID 40400573.

^ Leask A (June 2011). "The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis". Pharmacological Research. 63 (6): 502–03. doi:10.1016/j.phrs.2011.01.011. PMID 21315153.

^ Arnson Y, Amital H, Agmon-Levin N, Alon D, Sánchez-Castañón M, López-Hoyos M, Matucci-Cerinic M, Szücs G, Shapira Y, Szekanecz Z, Shoenfeld Y (June 2011). "Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature". Autoimmunity Reviews. 10 (8): 490–94. doi:10.1016/j.autrev.2011.02.002. PMID 21320645.

^ Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012).  Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS (eds.). "Scleroderma Workup". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 6 March 2014.

^ Jump up to: a b c d e f g Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012).  Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS (eds.). "Scleroderma". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 5 March 2014.

^ Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012).  Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS (eds.). "Scleroderma Differential Diagnoses". Medscape Reference. WebMD. Archived from the original on 6 March 2014. Retrieved 6 March 2014.

^ Elston, William D. James, Timothy G. Berger, Dirk M. (2006). Andrew's diseases of the skin: clinical dermatology (10 ed.). Philadelphia, PA: Saunders Elsevier. pp. 169–172. ISBN 978-0808923510.

^ Jump up to: a b Walker KM, Pope J (August 2012). "Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts". Seminars in Arthritis and Rheumatism. 42 (1): 42–55. doi:10.1016/j.semarthrit.2012.01.003. PMID 22464314.

^ Jump up to: a b Fett N (July–August 2013). "Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies". Clinics in Dermatology. 31 (4): 432–37. doi:10.1016/j.clindermatol.2013.01.010. PMID 23806160.

^ Jump up to: a b Shah AA, Wigley FM (April 2013). "My approach to the treatment of scleroderma". Mayo Clinic Proceedings. 88 (4): 377–93. doi:10.1016/j.mayocp.2013.01.018. PMC 3666163. PMID 23541012.

^ Jump up to: a b Kowal-Bielecka O, Bielecki M, Kowal K (2013). "Recent advances in the diagnosis and treatment of systemic sclerosis" (PDF). Polskie Archiwum Medycyny Wewnetrznej. 123 (1–2): 51–58. PMID 23344666. Archived (PDF) from the original on 2014-03-06.

^ Jump up to: a b Beyer C, Dees C, Distler JH (January 2013). "Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis". Archives of Dermatological Research. 305 (1): 1–8. doi:10.1007/s00403-012-1304-7. PMID 23208311. S2CID 25073736.

^ Jump up to: a b Leask A (June 2012). "Emerging targets for the treatment of scleroderma". Expert Opinion on Emerging Drugs. 17 (2): 173–79. doi:10.1517/14728214.2012.678833. PMID 22533795. S2CID 29026417.

^ Manno R, Boin F (November 2010). "Immunotherapy of systemic sclerosis". Immunotherapy. 2 (6): 863–78. doi:10.2217/imt.10.69. PMC 3059511. PMID 21091117.

^ Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T (April 2010). "Pharmacotherapy of systemic sclerosis". Expert Opinion on Pharmacotherapy. 11 (5): 789–806. doi:10.1517/14656561003592177. PMC 2837533. PMID 20210685.

^ Ong VH, Denton CP (May 2010). "Innovative therapies for systemic sclerosis". Current Opinion in Rheumatology. 22 (3): 264–72. doi:10.1097/BOR.0b013e328337c3d6. PMID 20190640. S2CID 24631979.

^ Jump up to: a b c d Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.[page needed]

^ Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.[page needed]

^ "Medscape Multispecialty – Home page". WebMD. Archived from the original on 13 November 2013. Retrieved 27 November 2013.[full citation needed]

^ Jump up to: a b Sticherling M (October 2012). "Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings". Journal der Deutschen Dermatologischen Gesellschaft. 10 (10): 705–18, quiz 716. doi:10.1111/j.1610-0387.2012.07999.x. PMID 22913330. S2CID 7422759.

^ Alenghat FJ (February 2016). "The Prevalence of Atherosclerosis in Those with Inflammatory Connective Tissue Disease by Race, Age, and Traditional Risk Factors". Scientific Reports. 6: 20303. Bibcode:2016NatSR...620303A. doi:10.1038/srep20303. PMC 4740809. PMID 26842423.

^ Ngian GS, Sahhar J, Wicks IP, Van Doornum S (August 2011). "Cardiovascular disease in systemic sclerosis--an emerging association?". Arthritis Research & Therapy. 13 (4): 237. doi:10.1186/ar3445. PMC 3239376. PMID 21888685.

^ Szekanecz É, Szamosi S, Horváth Á, Németh Á, Juhász B, Szántó J, Szücs G, Szekanecz Z (October 2012). "Malignancies associated with systemic sclerosis". Autoimmunity Reviews. 11 (12): 852–55. doi:10.1016/j.autrev.2012.02.021. PMID 22410174.

^ Shah AA, Rosen A (November 2011). "Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications". Current Opinion in Rheumatology. 23 (6): 530–35. doi:10.1097/BOR.0b013e32834a5081. PMC 3373179. PMID 21825998.

^ Onishi A, Sugiyama D, Kumagai S, Morinobu A (July 2013). "Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies". Arthritis and Rheumatism. 65 (7): 1913–21. doi:10.1002/art.37969. PMID 23576072.

^ Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A (January 2013). "Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies". Rheumatology. 52 (1): 143–54. doi:10.1093/rheumatology/kes303. PMID 23175568.

^ Kennedy N, Walker J, Hakendorf P, Roberts-Thomson P (23 March 2018). "Improving life expectancy of patients with scleroderma: results from the South Australian Scleroderma Register". Internal Medicine Journal. 48 (8): 951–56. doi:10.1111/imj.13799. PMID 29573101. S2CID 4230441.

^ Nikpour M, Stevens WM, Herrick AL, Proudman SM (December 2010). "Epidemiology of systemic sclerosis". Best Practice & Research. Clinical Rheumatology. 24 (6): 857–69. doi:10.1016/j.berh.2010.10.007. PMID 21665131.

^ Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, Hummers LK, Wigley FM (July 2013). "Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature". Medicine. 92 (4): 191–205. doi:10.1097/MD.0b013e31829be125. PMC 4553970. PMID 23793108.

^ Jump up to: a b c d Lidar M, Langevitz P (May 2012). "Pregnancy issues in scleroderma". Autoimmunity Reviews. 11 (6–7): A515–19. doi:10.1016/j.autrev.2011.11.021. PMID 22155199.


External links[edit]
Handout on Health: Scleroderma – US National Institute of Arthritis and Musculoskeletal and Skin Diseases
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}ClassificationDICD-10: L94.0–L94.1, M34ICD-9-CM: 701.0 710.1SNOMED CT: 201441006External resourcesMedlinePlus: 000429Orphanet: 801
.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteDiseases of the skin and appendages by morphologyGrowthsEpidermal
Wart
Callus
Seborrheic keratosis
Acrochordon
Molluscum contagiosum
Actinic keratosis
Squamous-cell carcinoma
Basal-cell carcinoma
Merkel-cell carcinoma
Nevus sebaceous
Trichoepithelioma
Pigmented
Freckles
Lentigo
Melasma
Nevus
Melanoma
Dermal andsubcutaneous
Epidermal inclusion cyst
Hemangioma
Dermatofibroma (benign fibrous histiocytoma)
Keloid
Lipoma
Neurofibroma
Xanthoma
Kaposi's sarcoma
Infantile digital fibromatosis
Granular cell tumor
Leiomyoma
Lymphangioma circumscriptum
Myxoid cyst
RashesWith epidermal involvementEczematous
Contact dermatitis
Atopic dermatitis
Seborrheic dermatitis
Stasis dermatitis
Lichen simplex chronicus
Darier's disease
Glucagonoma syndrome
Langerhans cell histiocytosis
Lichen sclerosus
Pemphigus foliaceus
Wiskott–Aldrich syndrome
Zinc deficiency
Scaling
Psoriasis
Tinea (Corporis
Cruris
Pedis
Manuum
Faciei)
Pityriasis rosea
Secondary syphilis
Mycosis fungoides
Systemic lupus erythematosus
Pityriasis rubra pilaris
Parapsoriasis
Ichthyosis
Blistering
Herpes simplex
Herpes zoster
Varicella
Bullous impetigo
Acute contact dermatitis
Pemphigus vulgaris
Bullous pemphigoid
Dermatitis herpetiformis
Porphyria cutanea tarda
Epidermolysis bullosa simplex
Papular
Scabies
Insect bite reactions
Lichen planus
Miliaria
Keratosis pilaris
Lichen spinulosus
Transient acantholytic dermatosis
Lichen nitidus
Pityriasis lichenoides et varioliformis acuta
Pustular
Acne vulgaris
Acne rosacea
Folliculitis
Impetigo
Candidiasis
Gonococcemia
Dermatophyte
Coccidioidomycosis
Subcorneal pustular dermatosis
Hypopigmented
Tinea versicolor
Vitiligo
Pityriasis alba
Postinflammatory hyperpigmentation
Tuberous sclerosis
Idiopathic guttate hypomelanosis
Leprosy
Hypopigmented mycosis fungoides
Without epidermal involvementRedBlanchable ErythemaGeneralized
Drug eruptions
Viral exanthems
Toxic erythema
Systemic lupus erythematosus
Localized
Cellulitis
Abscess
Boil
Erythema nodosum
Carcinoid syndrome
Fixed drug eruption
Specialized
Urticaria
Erythema (Multiforme
Migrans
Gyratum repens
Annulare centrifugum
Ab igne)
Nonblanchable PurpuraMacular
Thrombocytopenic purpura
Actinic/solar purpura
Papular
Disseminated intravascular coagulation
Vasculitis
Indurated
Scleroderma/morphea
Granuloma annulare
Lichen sclerosis et atrophicus
Necrobiosis lipoidica
Miscellaneous disordersUlcers

Hair
Telogen effluvium
Androgenic alopecia
Alopecia areata
Systemic lupus erythematosus
Tinea capitis
Loose anagen syndrome
Lichen planopilaris
Folliculitis decalvans
Acne keloidalis nuchae
Nail
Onychomycosis
Psoriasis
Paronychia
Ingrown nail
Mucous membrane
Aphthous stomatitis
Oral candidiasis
Lichen planus
Leukoplakia
Pemphigus vulgaris
Mucous membrane pemphigoid
Cicatricial pemphigoid
Herpesvirus
Coxsackievirus
Syphilis
Systemic histoplasmosis
Squamous-cell carcinoma

vteCutaneous keratosis, ulcer, atrophy, and necrobiosisEpidermal thickening
keratoderma: Keratoderma climactericum
Paraneoplastic keratoderma
Acrokeratosis paraneoplastica of Bazex
Aquagenic keratoderma
Drug-induced keratoderma
psoriasis
Keratoderma blennorrhagicum
keratosis: Seborrheic keratosis
Clonal seborrheic keratosis
Common seborrheic keratosis
Irritated seborrheic keratosis
Seborrheic keratosis with squamous atypia
Reticulated seborrheic keratosis
Dermatosis papulosa nigra
Keratosis punctata of the palmar creases
other hyperkeratosis: Acanthosis nigricans
Confluent and reticulated papillomatosis
Callus
Ichthyosis acquisita
Arsenical keratosis
Chronic scar keratosis
Hyperkeratosis lenticularis perstans
Hydrocarbon keratosis
Hyperkeratosis of the nipple and areola
Inverted follicular keratosis
Lichenoid keratosis
Multiple minute digitate hyperkeratosis
PUVA keratosis
Reactional keratosis
Stucco keratosis
Thermal keratosis
Viral keratosis
Warty dyskeratoma
Waxy keratosis of childhood
other hypertrophy: Keloid
Hypertrophic scar
Cutis verticis gyrata
Necrobiosis/granulomaNecrobiotic/palisading
Granuloma annulare
Perforating
Generalized
Subcutaneous
Granuloma annulare in HIV disease
Localized granuloma annulare
Patch-type granuloma annulare
Necrobiosis lipoidica
Annular elastolytic giant-cell granuloma
Granuloma multiforme
Necrobiotic xanthogranuloma
Palisaded neutrophilic and granulomatous dermatitis
Rheumatoid nodulosis
Interstitial granulomatous dermatitis/Interstitial granulomatous drug reaction
Foreign body granuloma
Beryllium granuloma
Mercury granuloma
Silica granuloma
Silicone granuloma
Zirconium granuloma
Soot tattoo
Tattoo
Carbon stain
Other/ungrouped
eosinophilic dermatosis
Granuloma faciale
Dermis/localized CTDCutaneous lupuserythematosus
chronic:  Discoid
Panniculitis
subacute: Neonatal
ungrouped: Chilblain
Lupus erythematosus–lichen planus overlap syndrome
Tumid
Verrucous
Rowell's syndrome
Scleroderma/Morphea
Localized scleroderma
Localized morphea
Morphea–lichen sclerosus et atrophicus overlap
Generalized morphea
Atrophoderma of Pasini and Pierini
Pansclerotic morphea
Morphea profunda
Linear scleroderma
Atrophic/atrophoderma
Lichen sclerosus
Anetoderma
Schweninger–Buzzi anetoderma
Jadassohn–Pellizzari anetoderma
Atrophoderma of Pasini and Pierini
Acrodermatitis chronica atrophicans
Semicircular lipoatrophy
Follicular atrophoderma
Linear atrophoderma of Moulin
Perforating
Kyrle disease
Reactive perforating collagenosis
Elastosis perforans serpiginosa
Perforating folliculitis
Acquired perforating dermatosis
Skin ulcer
Pyoderma gangrenosum
Other
Calcinosis cutis
Sclerodactyly
Poikiloderma vasculare atrophicans
Ainhum/Pseudo-ainhum

vteSystemic connective tissue disordersGeneralSystemic lupus erythematosus
Drug-induced SLE
Libman–Sacks endocarditis
Inflammatory myopathy
Myositis
Dermatopolymyositis
Dermatomyositis/Juvenile dermatomyositis
Polymyositis* Inclusion body myositis
Scleroderma
Systemic scleroderma
Progressive systemic sclerosis
CREST syndrome

Overlap syndrome / Mixed connective tissue disease
Other hypersensitivity/autoimmune
Sjögren syndrome
Other
Behçet's disease
Polymyalgia rheumatica
Eosinophilic fasciitis
Eosinophilia–myalgia syndrome
fibrillin
Marfan syndrome
Congenital contractural arachnodactyly

Authority control: National libraries  
France (data)
United States
Japan






